Pliant Therapeutics Initiates Phase 2a Trial Enrollment of Bexotegrast for Primary Sclerosing Cholangitis Treatment
Pliant Therapeutics, a biopharmaceutical company focused on treating fibrosis, has begun Phase 2a enrollment for its bexotegrast to treat primary sclerosing cholangitis (PSC). The trial follows a posi ...